Skip to main content
Erschienen in: World Journal of Urology 10/2016

20.02.2016 | Original Article

Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy

verfasst von: A. Sivaraman, G. Ordaz Jurado, X. Cathelineau, Eric Barret, P. Dell’Oglio, S. Joniau, M. Bianchi, A. Briganti, M. Spahn, P. Bastian, J. Chun, P. Chlosta, P. Gontero, M. Graefen, R. Jeffrey Karnes, G. Marchioro, B. Tombal, L. Tosco, H. Henk van der Poel, R. Sanchez-Salas

Erschienen in: World Journal of Urology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of the study was to identify the appropriate level of Charlson comorbidity index (CCI) in older patients (>70 years) with high-risk prostate cancer (PCa) to achieve survival benefit following radical prostatectomy (RP).

Methods

We retrospectively analyzed 1008 older patients (>70 years) who underwent RP with pelvic lymph node dissection for high-risk prostate cancer (preoperative prostate-specific antigen >20 ng/mL or clinical stage ≥T2c or Gleason ≥8) from 14 tertiary institutions between 1988 and 2014. The study population was further grouped into CCI < 2 and ≥2 for analysis. Survival rate for each group was estimated with Kaplan–Meier method and competitive risk Fine-Gray regression to estimate the best explanatory multivariable model. Area under the curve (AUC) and Akaike information criterion were used to identify ideal ‘Cut off’ for CCI.

Results

The clinical and cancer characteristics were similar between the two groups. Comparison of the survival analysis using the Kaplan–Meier curve between two groups for non-cancer death and survival estimations for 5 and 10 years shows significant worst outcomes for patients with CCI ≥ 2. In multivariate model to decide the appropriate CCI cut-off point, we found CCI 2 has better AUC and p value in log rank test.

Conclusion

Older patients with fewer comorbidities harboring high-risk PCa appears to benefit from RP. Sicker patients are more likely to die due to non-prostate cancer-related causes and are less likely to benefit from RP.
Literatur
1.
Zurück zum Zitat Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71CrossRefPubMed Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71CrossRefPubMed
2.
Zurück zum Zitat Sood A, Jeong W, Peabody JO, Hemal AK, Menon M (2014) Robot-assisted radical prostatectomy: inching toward gold standard. Urol Clin N Am 41(4):473–484CrossRef Sood A, Jeong W, Peabody JO, Hemal AK, Menon M (2014) Robot-assisted radical prostatectomy: inching toward gold standard. Urol Clin N Am 41(4):473–484CrossRef
3.
Zurück zum Zitat Sivaraman A, Sanchez-Salas R, Prapotnich D, Barret E, Mombet A, Cathala N, Rozet F, Galiano M, Cathelineau X (2015) Robotics in urological surgery: evolution, current status and future perspectives. Actas Urol Esp 39:9–10CrossRef Sivaraman A, Sanchez-Salas R, Prapotnich D, Barret E, Mombet A, Cathala N, Rozet F, Galiano M, Cathelineau X (2015) Robotics in urological surgery: evolution, current status and future perspectives. Actas Urol Esp 39:9–10CrossRef
4.
Zurück zum Zitat Giedelman CA, Abdul-Muhsin H, Schatloff O, Palmer K, Lee L, Sanchez-Salas R, Cathelineau X, Dávila H, Cavelier L, Rueda M, Patel V (2013) The impact of robotic surgery in urology. Actas Urol Esp 37(10):652–657CrossRefPubMed Giedelman CA, Abdul-Muhsin H, Schatloff O, Palmer K, Lee L, Sanchez-Salas R, Cathelineau X, Dávila H, Cavelier L, Rueda M, Patel V (2013) The impact of robotic surgery in urology. Actas Urol Esp 37(10):652–657CrossRefPubMed
5.
Zurück zum Zitat Eggener SE, Scardino PT, Walsh PC, Steuber T, Schlomm T, Köllermann J, Sauter G, Haese A, Heinzer H, Huland H, Graefen M (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185:869–875CrossRefPubMedPubMedCentral Eggener SE, Scardino PT, Walsh PC, Steuber T, Schlomm T, Köllermann J, Sauter G, Haese A, Heinzer H, Huland H, Graefen M (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185:869–875CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Isbarn H, Wanner M, Salomon G et al (2010) Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 106:37–43CrossRefPubMed Isbarn H, Wanner M, Salomon G et al (2010) Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 106:37–43CrossRefPubMed
7.
Zurück zum Zitat Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M (2012) Identifying the best candidate or radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 61:584–592CrossRefPubMed Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M (2012) Identifying the best candidate or radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 61:584–592CrossRefPubMed
8.
Zurück zum Zitat Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK (2011) Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117:2883–2891CrossRefPubMedPubMedCentral Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK (2011) Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117:2883–2891CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI (2011) A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur Urol 59:88–95CrossRefPubMed Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI (2011) A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur Urol 59:88–95CrossRefPubMed
10.
Zurück zum Zitat Cooperberg MR, Vickers AJ, Broering JM, Carroll PR (2010) Comparative risk adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116:5226–5234CrossRefPubMedPubMedCentral Cooperberg MR, Vickers AJ, Broering JM, Carroll PR (2010) Comparative risk adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116:5226–5234CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178:493–499CrossRefPubMed Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178:493–499CrossRefPubMed
12.
Zurück zum Zitat Spahn M, Joniau S, Gontero P, Jones JS, Fergany A, Kaouk J, Klein EA (2010) Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 58:1–7CrossRefPubMed Spahn M, Joniau S, Gontero P, Jones JS, Fergany A, Kaouk J, Klein EA (2010) Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 58:1–7CrossRefPubMed
13.
Zurück zum Zitat Miocinovic R, Berglund RK, Stephenson AJ et al (2011) avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology 77:946–950CrossRefPubMed Miocinovic R, Berglund RK, Stephenson AJ et al (2011) avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology 77:946–950CrossRefPubMed
14.
Zurück zum Zitat Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC (2010) What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 76:710–714CrossRefPubMed Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC (2010) What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 76:710–714CrossRefPubMed
15.
Zurück zum Zitat Donohue JF, Bianco FJ Jr, Kuroiwa K, Vickers AJ, Wheeler TM, Scardino PT, Reuter VA, Eastham JA (2006) Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 176:991–995CrossRefPubMedPubMedCentral Donohue JF, Bianco FJ Jr, Kuroiwa K, Vickers AJ, Wheeler TM, Scardino PT, Reuter VA, Eastham JA (2006) Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 176:991–995CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H, Klein EA, Scardino PT, Reuther A, Poppel HV, Graefen M, Huland H, Karakiewicz PI (2011) Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 107:765–770CrossRefPubMed Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H, Klein EA, Scardino PT, Reuther A, Poppel HV, Graefen M, Huland H, Karakiewicz PI (2011) Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 107:765–770CrossRefPubMed
17.
Zurück zum Zitat Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R (2013) Impact of Age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol 63:693–701CrossRefPubMed Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R (2013) Impact of Age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol 63:693–701CrossRefPubMed
18.
Zurück zum Zitat Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P (2011) Mortality among men with locally advanced prostate cancer managed with non-curative intent: a nationwide study in PCBaSe Sweden. Eur Urol 60:554–563CrossRefPubMed Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P (2011) Mortality among men with locally advanced prostate cancer managed with non-curative intent: a nationwide study in PCBaSe Sweden. Eur Urol 60:554–563CrossRefPubMed
19.
Zurück zum Zitat Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL (2011) Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 29:1335–1341CrossRefPubMedPubMedCentral Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL (2011) Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 29:1335–1341CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS (2011) Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 117:4642–4650CrossRefPubMed Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS (2011) Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 117:4642–4650CrossRefPubMed
21.
Zurück zum Zitat Abdollah F, Sun M, Schmitges J, Tian Z, Jeldres C, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI (2011) Cancer-specific and other cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol 60:920–930CrossRefPubMed Abdollah F, Sun M, Schmitges J, Tian Z, Jeldres C, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI (2011) Cancer-specific and other cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol 60:920–930CrossRefPubMed
22.
Zurück zum Zitat Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H (2002) Competing risk analysis after radical prostatectomy for clinically non-metastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 168:525–529CrossRefPubMed Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H (2002) Competing risk analysis after radical prostatectomy for clinically non-metastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 168:525–529CrossRefPubMed
23.
Zurück zum Zitat Sanchez-Salas R, Prapotnich D, Rozet F, Mombet A, Cathala N, Barret E, Galiano M, Cathelineau X, Vallancien G (2010) Laparoscopic radical prostatectomy is feasible and effective in ‘fit’ senior men with localized prostate cancer. BJU Int 106(10):1530–1536CrossRefPubMed Sanchez-Salas R, Prapotnich D, Rozet F, Mombet A, Cathala N, Barret E, Galiano M, Cathelineau X, Vallancien G (2010) Laparoscopic radical prostatectomy is feasible and effective in ‘fit’ senior men with localized prostate cancer. BJU Int 106(10):1530–1536CrossRefPubMed
24.
Zurück zum Zitat Everaerts W, Van Rij S, Reeves F, Costello A (2015) Radical treatment of localized prostate cancer in the elderly. BJU Int. doi:10.1111/bju.13128 Everaerts W, Van Rij S, Reeves F, Costello A (2015) Radical treatment of localized prostate cancer in the elderly. BJU Int. doi:10.​1111/​bju.​13128
Metadaten
Titel
Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy
verfasst von
A. Sivaraman
G. Ordaz Jurado
X. Cathelineau
Eric Barret
P. Dell’Oglio
S. Joniau
M. Bianchi
A. Briganti
M. Spahn
P. Bastian
J. Chun
P. Chlosta
P. Gontero
M. Graefen
R. Jeffrey Karnes
G. Marchioro
B. Tombal
L. Tosco
H. Henk van der Poel
R. Sanchez-Salas
Publikationsdatum
20.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 10/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1784-8

Weitere Artikel der Ausgabe 10/2016

World Journal of Urology 10/2016 Zur Ausgabe

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

D-Mannose ohne Nutzen in der Prävention von HWI-Rezidiven

D-Mannose, eine Hoffnungsträgerin in der Rezidivprophylaxe von Harnwegsinfektionen, hat in einer Studie nicht mehr bewirken können als ein Placebo. Die Empfehlung zur Einnahme entfalle damit, so die Autoren.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.